Drug Trial Radar · NCT06948006
A Study to Investigate the Relative Bioavailability of 2 Different Formulations of AZD4144, the Effect of Food and Omeprazole on the Pharmacokinetics of AZD4144 in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Jul 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Apr 23, 2025
Primary completion
Jun 27, 2025
Study completion Jun 27, 2025
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- Apr 28, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main aim of this study to compare the pharmacokinetics (PK) of two formulations of AZD4144 and assess the effect of food and omeprazole on PK of AZD4144 in healthy participants.
Conditions
- Healthy Participants
Interventions
AZD4144Drug
Participants will receive AZD4144 orally.
OmeprazoleDrug
Participants will receive omeprazole orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under concentration-time curve from time 0 to infinity (AUCinf) of AZD4144Time frame: Days 1-4, Days 8-11 and Days 15-18
- Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast) of AZD4144Time frame: Days 1-4, Days 8-11 and Days 15-18
- Maximum observed drug concentration (Cmax) of AZD4144Time frame: Days 1-4, Days 8-11 and Days 15-18
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Site
Harrow, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.